Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Novavax, Inc (NASDAQ: NVAX) closed the day trading at $7.25 up 1.68% from the previous closing price of $7.13. In other words, the price has increased by $1.68 from its previous closing price. On the day, 3.19 million shares were traded. NVAX stock price reached its highest trading level at $7.355 during the session, while it also had its lowest trading level at $7.09.
Ratios:
For a better understanding of NVAX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.27.
BofA Securities Downgraded its Neutral to Underperform on August 20, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1178117632 and an Enterprise Value of 666363712. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.10, and their Forward P/E ratio for the next fiscal year is 55.52. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.11. Its current Enterprise Value per Revenue stands at 0.626 whereas that against EBITDA is 1.475.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.57, which has changed by -0.34103513 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $11.55, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 2.00%, while the 200-Day Moving Average is calculated to be -0.96%.
Shares Statistics:
Over the past 3-months, NVAX traded about 3.91M shares per day on average, while over the past 10 days, NVAX traded about 3267200 shares per day. A total of 162.47M shares are outstanding, with a floating share count of 154.79M. Insiders hold about 4.74% of the company’s shares, while institutions hold 60.62% stake in the company. Shares short for NVAX as of 1765756800 were 52590573 with a Short Ratio of 13.45, compared to 1763078400 on 50682588. Therefore, it implies a Short% of Shares Outstanding of 52590573 and a Short% of Float of 32.479998.
Earnings Estimates
The market rating of Novavax, Inc (NVAX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.0, with high estimates of $0.32 and low estimates of -$0.34.
Analysts are recommending an EPS of between $2.91 and $1.18 for the fiscal current year, implying an average EPS of $2.15. EPS for the following year is $0.26, with 8.0 analysts recommending between $3.87 and -$0.94.
Revenue Estimates
8 analysts predict $90.26M in revenue for. The current quarter. It ranges from a high estimate of $167M to a low estimate of $71M. As of. The current estimate, Novavax, Inc’s year-ago sales were $88.31MFor the next quarter, 8 analysts are estimating revenue of $114.53M. There is a high estimate of $172.5M for the next quarter, whereas the lowest estimate is $58.9M.
A total of 9 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $1.05B, resulting in an average revenue estimate of $1.06B. In the same quarter a year ago, actual revenue was $682.16MBased on 9 analysts’ estimates, the company’s revenue will be $459.72M in the next fiscal year. The high estimate is $1.13B and the low estimate is $249.69M.
